Respiratory disease

BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics

Retrieved on: 
Freitag, Mai 3, 2024
University, Research and development, Radiation, Oncology, Research, Abstract, Immunotherapy, MD, University School, Cayetano Heredia University, Internet, Lung cancer, Radiation therapy, Johns Hopkins Hospital, International Association, Respiratory disease, Society, Lung, MD Anderson Cancer Center, Publication, Biomarker, Research institute, Esophageal cancer, Therapy, Cancer

The conference call and webinar will feature presentations by Key Opinion Leaders (KOLs) Trevor M. Feinstein, M.D.

Key Points: 
  • The conference call and webinar will feature presentations by Key Opinion Leaders (KOLs) Trevor M. Feinstein, M.D.
  • (MD Anderson Cancer Center), who will discuss below topics:
    Also featured will be a management discussion on technology platform and pipeline updates of SEED Therapeutics, BeyondSpring’s majority-owned molecular glue subsidiary.
  • He joined Piedmont Cancer Institute in 2011 and is the Director of Research at Piedmont Fayette Hospital.
  • Dr. Lin runs a translational research team that evaluates biomarkers for treatment response and disease outcomes after cancer therapy.

BioVie Presents Data Showing Potential for Bezisterim (NE3107) to Reduce Inflammation and Restore Homeostasis in a Manner Correlated with Alzheimer’s Disease and Biomarker Endpoints

Retrieved on: 
Donnerstag, April 25, 2024
Political moderate, Inflammation, International, M1, WHO, Notifiable disease, USAN, Liver disease, Homeostasis, Chronic obstructive pulmonary disease, World Health Organization, Randomness, Monocyte, CVD, Drug development, Sepsis, DNA methylation, Microglia, Doctor of Philosophy, Dementia, Respiratory disease, Disease, IBD, INN, DNA, CKD, Exercise, Data, Inflammatory bowel disease, Diet, Patient, Macrophage, Metabolism, Cardiovascular disease, Jools' Annual Hootenanny, PD, Cancer, Chronic kidney disease, Gene, COPD, Vaccine

The DNA methylation dataset assessed the extent of DNA methylation on roughly 965,000 individual sites where methyl groups can be attached to the patients’ DNA.

Key Points: 
  • The DNA methylation dataset assessed the extent of DNA methylation on roughly 965,000 individual sites where methyl groups can be attached to the patients’ DNA.
  • But these data provide evidence that bezisterim may have the potential to help keep people healthier for a longer time as we age,” said Cuong Do, BioVie’s President and CEO.
  • “BioVie believes that DNA methylation may not need to constantly increase as we age, and thus the progression of age-related disease may not be uni-directional.
  • This suggests that bezisterim disrupted the negative consequences of DNA methylation that promotes inflammation and restored homeostasis.

Co-Diagnostics, Inc. to Host Booth and Deliver Presentation at APRC 2024 in Taiwan

Retrieved on: 
Mittwoch, April 24, 2024
Sale, FDA, Learning, APRC, Tuberculosis, Business development, Conference, Infection, PCR, Respiratory disease, Notifiable disease, TB, COVID-19, Pharmaceutical industry

The theme for the 2024 conference is "Shaping a Safer World Through High-Quality Holistic Healthcare," reflecting the organizers' vision to discuss current evidence, share ideas and information, and accelerate innovation.

Key Points: 
  • The theme for the 2024 conference is "Shaping a Safer World Through High-Quality Holistic Healthcare," reflecting the organizers' vision to discuss current evidence, share ideas and information, and accelerate innovation.
  • Joseph Featherstone, the Company's Executive VP of Business Development, will be delivering a presentation on April 27th on accessible TB diagnostics on the Co-Dx PCR Pro™.
  • Attendees interested in learning more about Co-Dx and its products, including its upcoming Co-Dx PCR Pro instrument and tests, are invited to visit the Company at Booth B20.
  • The Co-Dx PCR Pro instrument and Co-Dx COVID-19 Test are currently under review by the FDA.

Boston Medical Center Study Furthers Understanding of Lung Regeneration

Retrieved on: 
Montag, April 22, 2024
Mortality, Boston Medical Center, BMC, Cell Stem Cell, Cell, Chronic obstructive pulmonary disease, Boston University, Transplant, Regenerative medicine, Health, Bacteria, Respiratory disease, MD, Doctor of Philosophy, Disease, Respiratory system, Engineering, Acute respiratory distress syndrome, Pulmonary fibrosis, AT1, Science, Medicine, Knowledge, Infection, COPD, Vaccine

BOSTON, April 22, 2024 /PRNewswire/ -- Researchers at Boston Medical Center (BMC) and Boston University (BU) today announced findings from a new research study, published in Cell Stem Cell, detailing the development of a method for generating human alveolar epithelial type I cells (AT1s) from pluripotent stem cells (iPSCs).

Key Points: 
  • BOSTON, April 22, 2024 /PRNewswire/ -- Researchers at Boston Medical Center (BMC) and Boston University (BU) today announced findings from a new research study, published in Cell Stem Cell, detailing the development of a method for generating human alveolar epithelial type I cells (AT1s) from pluripotent stem cells (iPSCs).
  • As science and medicine have progressed, researchers have identified a clear need for additional knowledge about lung cells to help improve patient health.
  • "Uncovering the ability to generate human alveolar epithelial type I cells (AT1s), and similar cell types, from pluripotent stem cells (iPSCs), has expanded our knowledge of biological processes and can significantly improve disease understanding and management," said Darrell Kotton, MD, Director, Center for Regenerative Medicine (CReM) of Boston University and Boston Medical Center.
  • This new study also furthers the CReM's goal of generating every human lung cell type from iPSCs as a pathway to improving disease management and provides a source of cells for future transplantation to regenerate damaged lung tissues in vivo.

How a new drug prototype regenerates lung tissue

Retrieved on: 
Mittwoch, April 10, 2024
Mortality, FDA, Idiopathic pulmonary fibrosis, Scripps Research, National library, National academy, Mouse, Cell, Kidney, World Health Organization, ReFrame, Research, IPF, Death, Respiratory disease, Doctor of Philosophy, DPP4, Rest, B cell, Human, COVID-19, Lung, Regenerative medicine, Biology, Heart failure, Clinical trial, Harvard University, Growth, Disease, Chronic obstructive pulmonary disease, Pharmaceutical industry

LA JOLLA, Calif., April 10, 2024 /PRNewswire/ -- Pulmonary diseases are a leading cause of morbidity and mortality worldwide. For many progressive lung diseases like idiopathic pulmonary fibrosis (IPF), a key issue is a low supply of new stem cells to repair and reverse damage. These cells are responsible for regenerating and increasing the growth of healthy tissue—without them, lung function decreases and a range of severe illnesses can take hold.

Key Points: 
  • "We chose the lung because the stem cell population of the lower airway doesn't regenerate as effectively as one ages."
  • However, there currently are no available treatment options that regenerate damaged lung tissue.
  • To see whether existing drug mechanisms could increase growth of lung stem cells, the team turned to ReFRAME , a drug repurposing library built by Calibr-Skaggs.
  • While NZ-97 is a prototype drug, it's chemically similar to CMR316, Calibr-Skagg's drug that will be entering a phase 1 clinical trial in a few months.

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases

Retrieved on: 
Montag, März 25, 2024
I&I, TARC, Atopic dermatitis, Disease, Half-life, Patient, SAN, Heel, IND, Respiratory disease, Asthma, SQ, Clinical trial, Therapy, Safety, Pharmacokinetics, Engineering, Pharmaceutical industry

SAN FRANCISCO and WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), COPD, asthma and other inflammatory and immunology (I&I) indications, today announced that it has initiated dosing of healthy volunteers in its first clinical trial for APG808, a novel subcutaneous (SQ) extended half-life monoclonal antibody (mAb) targeting IL-4Rα, which is being developed as a treatment for people living with moderate-to-severe COPD, asthma and other I&I diseases.

Key Points: 
  • COPD is a progressive respiratory disease that is estimated to affect approximately 10 percent of the global population 40 years of age and older.
  • Despite recent advancements in COPD treatment, a significant number of people continue to suffer and die from the disease.
  • The APG808 Phase 1 trial is designed as a double-blind, placebo-controlled, first-in-human, single-ascending dose trial in healthy volunteers.
  • Importantly, this points to potentially less frequent dosing for patients with COPD, which could significantly improve quality of life.”

Aspira Women’s Health Expands Senior Leadership Team with the Addition of Sandra Milligan, M.D., J.D. as President

Retrieved on: 
Montag, März 18, 2024
Georgetown University Law Center, Ovarian cancer, Development, Acceleration, California State University, Luminex Corporation, Information technology, Standard of care, Senior, Respiratory disease, University, Gynaecology, Woman, Doctor of Philosophy, Research and development, Endometriosis, Drug development, Dana–Farber Cancer Institute, Therapy, Amgen, DIA, Human resources, Medical device

AUSTIN, Texas, March 18, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that it has expanded its senior management team with the addition of Sandra Milligan, M.D., J.D. as President effective April 1, 2024. Dr. Milligan will report to Nicole Sandford, who will remain CEO. The Company has also promoted Dr. Todd Pappas, Vice President of Research & Development, to lead the Company’s product development team reporting directly to Dr. Milligan, following the departure of Dr. Jody Berry.

Key Points: 
  • The Company has also promoted Dr. Todd Pappas, Vice President of Research & Development, to lead the Company’s product development team reporting directly to Dr. Milligan, following the departure of Dr. Jody Berry.
  • She has demonstrated success in supporting pipeline and product development in both oncology and non-oncology disease areas, with recent emphasis in women’s health.
  • Dr. Milligan is a known and respected leader in women’s health who drives cross-functional strategies to achieve corporate success.
  • As President, Dr. Milligan will be a key member of the executive leadership team with direct responsibility for the Research and Development, Operations, Information Technology, and Human Resources functions.

Global Respiratory Care Devices Market Report, 2023-2024 and 2030: Infrastructure Improvements Key to Growth, Innovations in AI to Transform the Market Landscape - ResearchAndMarkets.com

Retrieved on: 
Montag, März 11, 2024
Medical Devices, Hospitals, Health, Health Technology, Medical Supplies, Hospital, Sleep apnea, Prevalence, Pneumonia, Emphysema, Tuberculosis, Intelligence, Incidence, Ageing, Patient, Respiratory therapist, Tissue, Chronic obstructive pulmonary disease, Research, Record, Quality of life, Human, Respiratory disease, Asthma, World Health Organization, CDC, Oxygen, WHO, TB, RMT, COPD, Allergy, Respiration, USD, Agonal respiration, Personal protective equipment

The rising incidence of respiratory diseases, which includes chronic obstructive pulmonary ailment, allergies, and sleep apnea, drives demand for respiration care devices.

Key Points: 
  • The rising incidence of respiratory diseases, which includes chronic obstructive pulmonary ailment, allergies, and sleep apnea, drives demand for respiration care devices.
  • This drives the demand for respiratory care devices to maintain adequate respiration and ensure most advantageous respiratory characteristic.
  • As the number of humans identified with respiration illnesses will increase, the demand for respiratory care devices is predicted to grow.
  • The Global Respiratory care devices marketplace requires a dependable and efficient infrastructure for low-earning individuals or healthcare centers.

Lindus Health Unveils Versatile "All-in-One Respiratory CRO" Offering Tailored to Respiratory Clinical Trials

Retrieved on: 
Dienstag, April 2, 2024
Sleep apnea, Pneumonia, MIT, Electronic data capture, Patient, Chronic obstructive pulmonary disease, Research, Pi, Health information management, EDC, Electronic health record, MD, Respiratory disease, Asthma, CTMS, Housing, Clinical trial management system, COPD, Data management, AptarGroup, Clinical data management, Fine chemical

Lindus Health has enrolled over 6,500 patients in respiratory clinical trials within the US, UK and Europe to date, showcasing their extensive resume of experience within this therapeutic area.

Key Points: 
  • Lindus Health has enrolled over 6,500 patients in respiratory clinical trials within the US, UK and Europe to date, showcasing their extensive resume of experience within this therapeutic area.
  • "We're thrilled to be launching a bespoke CRO offering to respiratory disease sponsors to mitigate the challenges faced in bringing essential respiratory therapies to market."
  • Deep regulatory and therapeutic area-specific expertise: Bringing together various research backgrounds, the Lindus Health team resumes exceptional expertise within respiratory clinical trials and the ever-changing regulatory landscapes of the US, UK, and EU.
  • Lindus Health is committed to leading successful respiratory research, providing a robust and efficient framework for clinical trials from inception to completion, and enhancing the experience for both sponsors and participants.

Vapotherm to Unveil Access365 Home Ventilation Solution at MEDTRADE

Retrieved on: 
Freitag, März 15, 2024
Hypercapnia, Respironics, VAPO, Business, Patient, Mechanical ventilation, Spirometry, Business development, Quality of life, Respiratory disease, OTCQX, NIV, COPD, FDA, HME, Hospital

EXETER, N.H., March 15, 2024 /PRNewswire/ -- Vapotherm, Inc., (OTCQX: VAPO), ("Vapotherm" or the "Company") today announced the debut of its Access365™ Home Ventilation Solution at the upcoming MEDTRADE conference.

Key Points: 
  • EXETER, N.H., March 15, 2024 /PRNewswire/ -- Vapotherm, Inc., (OTCQX: VAPO), ("Vapotherm" or the "Company") today announced the debut of its Access365™ Home Ventilation Solution at the upcoming MEDTRADE conference.
  • Dr. Jessica Whittle, Chief Medical Officer of Vapotherm, emphasized the company's commitment to improving the lives of hypercapnic patients in the home.
  • "(1)
    The highly anticipated Access365 home ventilator will be unveiled at MEDTRADE Dallas on March 27th.
  • Joe Army, President and CEO of Vapotherm, underscored the significance of the solution, stating, "Vapotherm is committed to supporting patients both in and out of the hospital.